



**ASX Announcement
3 February 2017**

Lifespot Health Ltd about to enter new market segment of coagulation home monitoring

- **Lifespot 100% owned subsidiary BodyTel to integrate Roche's new Bluetooth enabled PT/INR device 'CoaguChek® INRange'**
- **New PT/INR device completes product range of wirelessly communicating vital sensors for the company's chronic disease management offering**
- **Home monitoring will set a new standard of care for anticoagulated patients**

Lifespot Health (ASX: LSH), an international digital health company focused on the management and monitoring of chronic diseases, is pleased to announce that its 100% owned subsidiary, BodyTel GmbH and Roche Diagnostics Deutschland GmbH, have signed an agreement to integrate Roche's newly developed Bluetooth enabled PT/INR device 'CoaguChek® INRange' into BodyTel's telemedical platform.

The new device is the first Bluetooth enabled PT/INR home health device that helps patients and their healthcare providers to have greater control over their coagulation status. It targets patients who are in need of anticoagulation medication. These so called 'blood thinners' reduce the risk of heart attacks and stroke by reducing the formation of blood clots in arteries and veins. Studies have proven that people that already had an event like stroke or 'mini-stroke' are at high risk for a second similar event or other serious medical problems for at least five years.¹ Telemonitoring of INR values can help to develop appropriate prevention programs for those people.

The new device will smoothly get in line with BodyTel's existing range of Bluetooth enabled vital sensors already including blood glucose, blood pressure, weight and activity monitoring.

BodyTel's strategy is to incorporate best of breed sensors from third party suppliers into its medically certified telehealth system to let them send measured values into BodyTel's mobile apps and medial data cloud. From there data can be transferred into other professional applications or be viewed by patients and their authorized caregivers in BodyTel's own webportal.

Stefan Schraps, managing director of BodyTel remarks: “Home- and telemonitoring of the coagulation status is an exciting developing market where evidence already exists that home testing on a regular basis and communicating these values to healthcare providers helps patients to stay in their therapeutic range. As a result, payers can save significant money which otherwise would be spent on follow up care for patients that are severely affected in their health after a second similar event. Once integration is completed, we will be able to address insurance companies, monitoring centers, clinics and doctors offices enrolling patients on this device by offering a complete monitoring solution.”

Integration is expected to be done in the next months. The Company is pleased to provide this update and will continue to provide updates as appropriate.

For further information on the Company’s portfolio of projects please refer to the website at: www.lifespot-health.com

For further information:

Mr Niv Dagan

Corporate Advisor

Peak Asset Management

Phone: 1300 304 460

Mobile: 0402 912 198

Mr Justyn Stedwell

Company Secretary

Lifespot Health Ltd

Phone: 03 9041 6663

About Coagulation Home Monitoring

PT/INR is an internationally standardized measurement that describes how fast the blood coagulates.

Patient self-testing with CoaguChek® INRange sets a new standard of care by enabling healthcare providers to monitor patients’ INR data, while reducing their need to make continuous visits to doctor’s offices and clinics for such examinations.

It has been proven that patients who adhere more to their monitoring therapy, spend more time in their therapeutic range which results in lower incidences of stroke² or bleedings³. It has been demonstrated that 50–60% of patients can be expected to remain in their target range if the monitoring of INR occurs monthly, 77–85% if monitored weekly and up to 92% if monitored every three days.⁴

This is most important for people that have severe atrial fibrillation (AFib), artificial heart valves, thrombophilia or a ventricular assist device (VAD).

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About Lifespot Health Ltd.

Lifespot Health operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money.

Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients to monitor chronic diseases and critical conditions with their smartphones.

Lifespot Health aims to become the number one global player in the management and monitoring of chronic diseases. For more information, please visit www.lifespot-health.com.

¹ Public Release, 7-Oct-2014 Heart and Stroke Foundation of Canada, https://www.eurekalert.org/pub_releases/2014-10/hasf-spp100214.php

² Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet*. 2012;379:322-334.

³ Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J.M., Perera, R., Meats, E., Glasziou, P. (2006). Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. *Lancet* 367, 404–411.

⁴ Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. *Br J Haematol*. 2004;126(4):557-654.